Icon
+91 94997 68112
Login Register

Tasigna - (150mg, 200mg Capsule oral)

NILOTINIB HYDROCHLORIDE MONOHYDRATE Novartis
150mg, 200mg Capsule oral
Less Than $1000 mn
Less Than 5
Less Than 5
More Than 5
Less Than 5
Less Than 5
 None
Tasigna (nilotinib) is a cancer medicine that interferes with the growth and spread of cancer cells in the body. Tasigna is used to treat a type of blood cancer called Philadelphia chromosome positive chronic myeloid leukemia (CML) in adults and children who are at least 1 year old
Yes
**** ** ** ***** *** *** ******* ** *** *********. ** ****** **** *** ******* ******* ***** **** *** ** ****** ******* ******** ** *** *, **** *** **** ** ********** *** ******* ******* **. **** *** ****** ******* ** ***** **** **** ***** ** *** ***. ****** ******** * ********* ******** *** ******* ** *** **** (*****://***.**********.***.***/**********_****/*********/****/*****************_***.***) *** *** *** *********.
Tasigna Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7
****** **** *** *** ********* *** ********* (***** ******) *** ********* *** ********* *** ********* *** ********* (***** ******)
**** ******* **** **** ******* ******* ******* ******* ******* *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
****** *** \ ********* -**- *** ********* ******** ************ ****** **** ********
**** ** \ ** *** **, **** ******* **** ******* *** **** *** *** ****
  1. *** *, **** : * ****-** ** ***** *** ***** ** *** *** *******.
  2. *** **, **** : ****** ******** * ********* ******** *** ******* (*****://***.**********.***.***/**********_****/*********/****/*****************_***.***) *** *** *** *********
  3. *** **, **** : **** ******** ******** ***** *** **** ** ******.
  4. *** *, **** : ******** **** **** **** ************ ** ****** ** '***, '***, '***, '***, '*** *** '***.
  5. *** *, **** : ******** *** ********* ********** ******* ****. ** ****** ** ** ** **********.
  6. *** *, **** : *** *** ********* ********. *** ** *** *********. ** ** ****** **** ***** **** ***** **** ***.
  7. *** **, **** : ****** *** ********. ****** ** *** *********. ** ** ****** **** ***** **** ***** **** ***.

Tasigna - (50 mg; Capsule)

NILOTINIB HYDROCHLORIDE MONOHYDRATE Novartis
50 mg; Capsule
Less Than $1000 mn
Less Than 5
Less Than 5
More Than 5
Less Than 5
Less Than 5
 None
Tasigna is indicated for the treatment of adult patients with chronic phase and accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia (Ph+ CML) resistant or intolerant to prior therapy that included imatinib
Yes
* **** ** ***** ** ******* *******. ********* ** ******** *** ******, ******* ****** ** ******* ****** ** **** ** *** (*****://***.***.***/********/*****/****/**********/******************/**********.***). ****** ******** * ********* ******** *** ******* ** *** **** (*****://***.**********.***.***/**********_****/*********/****/*****************_***.***) *** *** *** *********.
Tasigna Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7
****** **** *** *** ********* *** ********* *** ********* *** ********* *** ********* *** *********
**** ******* **** **** ******* ******* ******* ******* ******* *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
****** *** \ ********* -**- *** ********* ******** ************ ****** **** ********
**** ** \ ** *** **, **** ******* **** ******* *** **** *** *** ****
  1. *** **, **** : * **** ** ***** ** ******* *******.
  2. *** **, **** : ****** ******** * ********* ******** *** ******* (*****://***.**********.***.***/**********_****/*********/****/*****************_***.***) *** *** *** *********
  3. *** **, **** : **** ******** ******** ***** *** **** ** ******.
  4. *** *, **** : ******** **** **** **** ************ ** ****** ** '***, '***, '***, '***, '*** *** '***.
  5. *** *, **** : ******** *** ********* ********** ******* ****. ** ****** ** ** ** **********.
  6. *** *, **** : *** *** ********* ********. *** ** *** *********. ** ** ****** **** ***** **** ***** **** ***.
  7. *** **, **** : ****** *** ********. ****** ** *** *********. ** ** ****** **** ***** **** ***** **** ***.

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.   Privacy Policy.   Terms and Conditions.